IR@PKUHSC  > 北京大学深圳医院
学科主题临床医学
Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening The Shenzhen Cervical Cancer Screening Trial I
Wu, Ruifang1; Belinson, Suzanne Elizabeth2; Du, Hui1; Na, Wulan1; Qu, Xinfeng3; Wu, Ruosong3; Liu, Ying1; Wang, Chun1; Zhou, Yanqiu1; Zhang, Lijie1; Belinson, Jerome L.2,4
关键词HPV APTIMA Screening Cervical cancer
刊名INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2010-11-01
DOI10.1111/IGC.0b013e3181f29547
20期:8页:1411-1414
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Obstetrics & Gynecology
研究领域[WOS]Oncology ; Obstetrics & Gynecology
关键词[WOS]PERFORMANCE ; DETECT
英文摘要

Introduction: Testing for high-risk types of human papillomavirus (HPV) has been consistently more sensitive than cervical cytology for high-grade precancers and cancers of the cervix (cervical intraepithelial neoplasia grade 2 or higher) but less specific. New assays are being developed to improve on the overall accuracy of molecular testing. The Gen-Probe APTIMA HPV assay (AHPV) is a multiplex assay that qualitatively detects 14 HPV types in a single tube. Because the AHPV targets HPV-E6/E7 messenger RNA transcripts, it should theoretically have a greater specificity than HPV assays that detect HPV DNA. The objective of this study was to compare the sensitivity and the specificity of the Gen-Probe AHPV with those of the Qiagen Hybrid Capture 2 assay (HC2) and liquid-based cytologic examination for cervical cancer screening.

Methods: A total of 2098 unscreened or poorly screened women 25 to 59 years of age were recruited in the city of Shenzhen, China. Two cervical specimens were collected: 1 in SurePath liquid for cytologic examination and 1 in PreservCyt for HPV testing by HC2 and the AHPV. The testing was performed by blinded technicians according to the manufacturer′s instructions. Women who had atypical squamous cells of undetermined significance or worse cytologic diagnosis and/or were HPV positive by either assay were asked to return for colposcopy and biopsy.

Results: Overall, 2095 women had complete data. Overall, 16.5% of the women were positive on HC2, 10.1% were positive on the AHPV, 5.45% had atypical squamous cells of undetermined significance or greater on cytologic examination, and 1.4% had histologically confirmed cervical disease: cervical intraepithelial neoplasia grade 2 or higher. The sensitivity values of liquid-based cytologic examination, HC2, and the AHPV were 66.7%, 88.9%, and 100%, respectively. The specificity values were 95.5%, 84.5%, and 91.2%, respectively. The AHPV was significantly more accurate by receiver operating characteristic curve comparison (P = 0.005).

Conclusions: The low false-positive rate (high specificity) and the high sensitivity of the AHPV makes this assay suitable for use as a primary assay for detecting cervical disease in a screening setting.

语种英语
WOS记录号WOS:000283850500023
资助机构Peking University Shenzhen Hospital, Shenzhen, China ; Royal Ladies Gynecology Clinic, Shenzhen, China ; Preventive Oncology International, Inc, Cleveland Heights, OH ; Gen-Probe, Inc, San Diego, CA ; Qiagen, Inc, Gaithersburg, MD
引用统计
被引频次:31[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62894
专题北京大学深圳医院
北京大学口腔医学院_口腔正畸科
作者单位1.Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
2.Prevent Oncol Int Inc, Cleveland Hts, OH 44118 USA
3.Royal Ladies Gynecol Clin, Shenzhen, Peoples R China
4.Cleveland Clin, Cleveland, OH 44106 USA
推荐引用方式
GB/T 7714
Wu, Ruifang,Belinson, Suzanne Elizabeth,Du, Hui,et al. Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening The Shenzhen Cervical Cancer Screening Trial I[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,2010,20(8):1411-1414.
APA Wu, Ruifang.,Belinson, Suzanne Elizabeth.,Du, Hui.,Na, Wulan.,Qu, Xinfeng.,...&Belinson, Jerome L..(2010).Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening The Shenzhen Cervical Cancer Screening Trial I.INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,20(8),1411-1414.
MLA Wu, Ruifang,et al."Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening The Shenzhen Cervical Cancer Screening Trial I".INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 20.8(2010):1411-1414.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wu, Ruifang]的文章
[Belinson, Suzanne Elizabeth]的文章
[Du, Hui]的文章
百度学术
百度学术中相似的文章
[Wu, Ruifang]的文章
[Belinson, Suzanne Elizabeth]的文章
[Du, Hui]的文章
必应学术
必应学术中相似的文章
[Wu, Ruifang]的文章
[Belinson, Suzanne Elizabeth]的文章
[Du, Hui]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。